Last $0.06 USD
Change Today 0.00 / 0.00%
Volume 2.8K
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6440 Flying Cloud Drive

Suite 101

Eden Prairie, MN 55416

United States

Phone: 952-476-9093

Fax: 952-698-4499

ProUroCare Medical Inc., a development stage company, develops for market products for the detection and characterization of male urological prostate disease. ProUroScan Prostate Imaging System The primary focus of the company is the prostate imaging device, known as the ProUroScan System, which is designed to produce an elasticity image of the prostate as an adjunctive aid in visualizing and documenting abnormalities of the prostate that have been detected by digital rectal examination. The ProUroScan System creates images and documents abnormalities of the prostate using the company’s new, proprietary mechanical elasticity imaging technology. In 2012, the ProUroScan received initial clearance for marketing in the United States from the United States Food and Drug Administration (FDA). The company’s imaging technology is based on work performed by Artann Laboratories, Inc. (Artann), a scientific technology company based in Trenton, New Jersey, focused on early-stage technology development. In addition to patented technology owned by the company, it has entered into license and development and commercialization agreements with Artann relating to their existing technology and know-how and all future technology developed by Artann in the urological field of use. The ProUroScan System is a new technology that offers patients and their physicians the ability to generate images of the abnormalities in the prostate in real-time following a positive digital rectal exam. The company’s patented tactile elasticity imaging technology, which uses a handheld pressure-sensing rectal probe and image construction software to produce its prostate maps, represents a new imaging modality distinct from traditional ultrasound imaging. Suppliers The company’s supplier includes Pressure Profile Systems, Inc. Strategy The company’s major business strategies include establishing prostate mechanical (elasticity) imaging as a standard of care for detecting abnormalities in the prostate; in collaboration with a strategic partner, drive market adoption; expand and protect its intellectual property position; seeking coverage and reimbursement for the ProUroScan imaging procedure; and utilizing its imaging technology for additional clinical applications and indications. Intellectual Property The company owns patents, patent applications, and know-how associated with mechanical prostate-imaging systems. These patents and patent applications include ‘Real Time Mechanical Imaging of the Prostate’, U.S. Patent No. 6,569,108 (expires December 2021) and ‘Method and Device for Elasticity Imaging’, U.S. Patent No. 5,524,636 (expires June 2013). In addition, it has one provisional U.S. patent application, eight foreign patents, and one foreign patent application that are related to the U.S. patents. Additionally, Artann has six U.S. patents, two U.S. patent applications, a foreign patent, and a foreign patent application that are licensed to the company under the Artann license agreement. The patents are U.S. Patent Nos. 7,819,824 (Method and Dual-Array Transducer Probe for Real Time Imaging of Prostate), 7,922,674 (Method and Device for Real Time Imaging of the Prostate), 8,142,368 (Method of Characterization and Differentiation of Tissue), 7,947,001 (Method and Devices for Measuring Structural and Elastic Properties of a Hollow Organ), 8,069,735 (Tactile Sensor Array for Soft Tissue Elasticity Imaging), and 8,016,777 (Handheld Probe for Prostate Cancer Screening). These patents begin expiring in 2029. Government Regulation The ProUroScan System is subject to the Food, Drug, and Cosmetics Act as implemented and enforced by the FDA and by comparable agencies in various states and various foreign countries. History ProUroCare Medical Inc. was founded in 1999. The company was incorporated in 1999 as a Minnesota corporation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PUMD:US $0.06 USD 0.00

PUMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PUMD.
View Industry Companies
 

Industry Analysis

PUMD

Industry Average

Valuation PUMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROUROCARE MEDICAL INC, please visit www.prourocare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.